Using Augmented Intelligence at the Point-of-Care to Eliminate Cervical Cancer

Ariel Beery¹, Adi Jacobson², ¹ Co-Founder and CEO, MobileODT, Tel Aviv, Israel, ² VP of Revenue, MobileODT, Tel Aviv, Israel

- **Investment Rational**
  MobileODT’s Enhanced Visual Assessment (EVA) System has transformed cervical cancer screening by making it mobile, affordable, and applying an AI diagnostic to disrupt the current methods of less reliable and accessible screening in order to save women’s lives from an entirely preventable disease.

- **Business Strategy**
  MobileODT will use the EVA System to deploy the Automated Visual Assessment (AVE) algorithm developed in partnership with the US National Cancer Institute. AVE will enable healthcare providers to detect cervical cancer at the point-of-care with a single cervical image. The EVA System is scaling rapidly, doubling users annually, and will impact the lives of millions of women by 2020.

- **Core Technology**
  At its core, the EVA System is a mobile and connected colposcope used to visualize the cervix. Its uniqueness is the ability to provide real-time data and implement live-saving AI unlike any currently available. With AVE detecting cancer with over 90% accuracy, the EVA System is poised to replace current testing standards (Pap Smear/71% accuracy) - a multi-million-dollar industry.

- **Product Profile/Pipeline**
  Partnerships with the US National Cancer Institute and a multinational pilot by CHAI (sponsored by UNITAID) to validate AVE for cervical cancer screening, will enable the World Health Organization to adopt our AI into its standard of care recommendations. Additional strategic partners conducting prospective trials include Apollo Hospitals (India), and clinical networks in Nigeria, South Korea, Poland, and the US.

- **What’s Next?**
  MobileODT has two prospective paid pilots of its AI running, in Korea and Poland, and another launching in India. We have commenced the process for CE and FDA clearance for widespread use of AVE with the EVA System. MobileODT is raising its Series B to accelerate its Go-to-Market, and ensure MobileODT is first-to-market, first-to-scale AI for cervical cancer.